Discover the Australian Advantage: Clinical Trials and R&D Tax Benefits
Australia is a leading destination for conducting clinical trials due to its streamlined regulatory approval process, world-class research infrastructure and attractive R&D tax incentives.
Why Conduct Clinical Trials in Australia?
- Most clinical trials are approved through the Clinical Trial Notification Scheme, enabling fast start-up times from approval to first patient in
- Research Infrastructure is world class, with state-of-the art facilities and a highly trained workforce for the conduct and oversight of clinical trials
- Australia’s multicultural population allows for ethnically diverse patient recruitment
- Clinical Trials in Australia follow strict GCP standards, with clinical data accepted by the FDA and EMA.
- No IND required to conduct clinical trials in Australia
- Clinical trials undertaken in Australia do not require US FDA Investigational New Drug (IND) application approval
- Strong Intellectual Protection regime, internationally recognised
- Australia has a stable political environment
- The Australian government R&D Tax Incentive – eligible companies may claim up to 43.5% cash back. For more information on the R&D Tax Incentive, Resonance Health can connect you to R&D Tax Consultants to help you determine your eligibility and maximise your tax benefits.
Resonance Health offers imaging CRO services for clinical trials. We specialise in the development and commercialisation of non-invasive medical imaging analysis (Software as a Medical Device, SaMD) for use in clinical trials as well as diagnostics and patient management. Our core commercial products have regulatory approval, and for clinical trials we can develop bespoke research tools tailored to the organ of interest.